Cargando…
Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium
BACKGROUND: Endothelin-1 (ET-1) and adrenomedullin (ADM) are commonly known as vasoactive peptides that regulate vascular homeostasis. Less recognised is the fact that both peptides could affect glucose metabolism. Here, we investigated whether ET-1 and ADM, measured as C-terminal-proET-1 (CT-proET-...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185875/ https://www.ncbi.nlm.nih.gov/pubmed/35681200 http://dx.doi.org/10.1186/s12933-022-01513-9 |
_version_ | 1784724814698643456 |
---|---|
author | Sujana, Chaterina Salomaa, Veikko Kee, Frank Seissler, Jochen Jousilahti, Pekka Neville, Charlotte Then, Cornelia Koenig, Wolfgang Kuulasmaa, Kari Reinikainen, Jaakko Blankenberg, Stefan Zeller, Tanja Herder, Christian Mansmann, Ulrich Peters, Annette Thorand, Barbara |
author_facet | Sujana, Chaterina Salomaa, Veikko Kee, Frank Seissler, Jochen Jousilahti, Pekka Neville, Charlotte Then, Cornelia Koenig, Wolfgang Kuulasmaa, Kari Reinikainen, Jaakko Blankenberg, Stefan Zeller, Tanja Herder, Christian Mansmann, Ulrich Peters, Annette Thorand, Barbara |
author_sort | Sujana, Chaterina |
collection | PubMed |
description | BACKGROUND: Endothelin-1 (ET-1) and adrenomedullin (ADM) are commonly known as vasoactive peptides that regulate vascular homeostasis. Less recognised is the fact that both peptides could affect glucose metabolism. Here, we investigated whether ET-1 and ADM, measured as C-terminal-proET-1 (CT-proET-1) and mid-regional-proADM (MR-proADM), respectively, were associated with incident type 2 diabetes. METHODS: Based on the population-based Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium data, we performed a prospective cohort study to examine associations of CT-proET-1 and MR-proADM with incident type 2 diabetes in 12,006 participants. During a median follow-up time of 13.8 years, 862 participants developed type 2 diabetes. The associations were examined in Cox proportional hazard models. Additionally, we performed two-sample Mendelian randomisation analyses using published data. RESULTS: CT-proET-1 and MR-proADM were positively associated with incident type 2 diabetes. The multivariable hazard ratios (HRs) [95% confidence intervals (CI)] were 1.10 [1.03; 1.18], P = 0.008 per 1-SD increase of CT-proET-1 and 1.11 [1.02; 1.21], P = 0.016 per 1-SD increase of log MR-proADM, respectively. We observed a stronger association of MR-proADM with incident type 2 diabetes in obese than in non-obese individuals (P-interaction with BMI < 0.001). The HRs [95%CIs] were 1.19 [1.05; 1.34], P = 0.005 and 1.02 [0.90; 1.15], P = 0.741 in obese and non-obese individuals, respectively. Our Mendelian randomisation analyses yielded a significant association of CT-proET-1, but not of MR-proADM with type 2 diabetes risk. CONCLUSIONS: Higher concentrations of CT-proET-1 and MR-proADM are associated with incident type 2 diabetes, but our Mendelian randomisation analysis suggests a probable causal link for CT-proET-1 only. The association of MR-proADM seems to be modified by body composition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01513-9. |
format | Online Article Text |
id | pubmed-9185875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91858752022-06-11 Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium Sujana, Chaterina Salomaa, Veikko Kee, Frank Seissler, Jochen Jousilahti, Pekka Neville, Charlotte Then, Cornelia Koenig, Wolfgang Kuulasmaa, Kari Reinikainen, Jaakko Blankenberg, Stefan Zeller, Tanja Herder, Christian Mansmann, Ulrich Peters, Annette Thorand, Barbara Cardiovasc Diabetol Research BACKGROUND: Endothelin-1 (ET-1) and adrenomedullin (ADM) are commonly known as vasoactive peptides that regulate vascular homeostasis. Less recognised is the fact that both peptides could affect glucose metabolism. Here, we investigated whether ET-1 and ADM, measured as C-terminal-proET-1 (CT-proET-1) and mid-regional-proADM (MR-proADM), respectively, were associated with incident type 2 diabetes. METHODS: Based on the population-based Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) Consortium data, we performed a prospective cohort study to examine associations of CT-proET-1 and MR-proADM with incident type 2 diabetes in 12,006 participants. During a median follow-up time of 13.8 years, 862 participants developed type 2 diabetes. The associations were examined in Cox proportional hazard models. Additionally, we performed two-sample Mendelian randomisation analyses using published data. RESULTS: CT-proET-1 and MR-proADM were positively associated with incident type 2 diabetes. The multivariable hazard ratios (HRs) [95% confidence intervals (CI)] were 1.10 [1.03; 1.18], P = 0.008 per 1-SD increase of CT-proET-1 and 1.11 [1.02; 1.21], P = 0.016 per 1-SD increase of log MR-proADM, respectively. We observed a stronger association of MR-proADM with incident type 2 diabetes in obese than in non-obese individuals (P-interaction with BMI < 0.001). The HRs [95%CIs] were 1.19 [1.05; 1.34], P = 0.005 and 1.02 [0.90; 1.15], P = 0.741 in obese and non-obese individuals, respectively. Our Mendelian randomisation analyses yielded a significant association of CT-proET-1, but not of MR-proADM with type 2 diabetes risk. CONCLUSIONS: Higher concentrations of CT-proET-1 and MR-proADM are associated with incident type 2 diabetes, but our Mendelian randomisation analysis suggests a probable causal link for CT-proET-1 only. The association of MR-proADM seems to be modified by body composition. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01513-9. BioMed Central 2022-06-09 /pmc/articles/PMC9185875/ /pubmed/35681200 http://dx.doi.org/10.1186/s12933-022-01513-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sujana, Chaterina Salomaa, Veikko Kee, Frank Seissler, Jochen Jousilahti, Pekka Neville, Charlotte Then, Cornelia Koenig, Wolfgang Kuulasmaa, Kari Reinikainen, Jaakko Blankenberg, Stefan Zeller, Tanja Herder, Christian Mansmann, Ulrich Peters, Annette Thorand, Barbara Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium |
title | Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium |
title_full | Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium |
title_fullStr | Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium |
title_full_unstemmed | Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium |
title_short | Associations of the vasoactive peptides CT-proET-1 and MR-proADM with incident type 2 diabetes: results from the BiomarCaRE Consortium |
title_sort | associations of the vasoactive peptides ct-proet-1 and mr-proadm with incident type 2 diabetes: results from the biomarcare consortium |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185875/ https://www.ncbi.nlm.nih.gov/pubmed/35681200 http://dx.doi.org/10.1186/s12933-022-01513-9 |
work_keys_str_mv | AT sujanachaterina associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT salomaaveikko associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT keefrank associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT seisslerjochen associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT jousilahtipekka associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT nevillecharlotte associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT thencornelia associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT koenigwolfgang associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT kuulasmaakari associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT reinikainenjaakko associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT blankenbergstefan associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT zellertanja associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT herderchristian associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT mansmannulrich associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT petersannette associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT thorandbarbara associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium AT associationsofthevasoactivepeptidesctproet1andmrproadmwithincidenttype2diabetesresultsfromthebiomarcareconsortium |